**TAM Depletion vs Reprogramming: Why Both Have Merit

Time: 3:29 pm
day: Day One


• Sharing lessons learned from depleting macrophages in cancer patients

• Providing ipdates on clinical development of emactuzumab, aCSF1R blocking antibody that depletes tumor-associated macrophages (TAM)

• Harnessing TAM heterogeneity to design novel TAM reprogramming agents

**Unfortunately Carola is unable to join us in person, but her slides will be made available post-event